Tirzepatide
GIP / GLP-1 Dual Agonist
Half-life: ~5 days (SC injection)
Research Profile
Relative research assessments — educational reference only.
Target Receptors
Buying peptides in Bali?
See community-reported Bali price ranges for Tirzepatide and 9 other compounds — clinic menus, WhatsApp quotes and import realities.
Open the Bali Price Index →Critical Research Warning
For educational reference only. As a dual agonist, Tirzepatide exerts potent metabolic effects. Animal studies mandate a warning regarding thyroid C-cell tumors.
"A 39-amino acid synthetic peptide that simultaneously activates GIP and GLP-1 receptors. Demonstrated greater weight loss than any approved single-agonist in clinical trials."
Full Description
Tirzepatide is a first-in-class glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 dual receptor agonist. Its 39-amino acid backbone is based on the native GIP sequence with GLP-1 receptor agonism built in. The dual mechanism provides synergistic metabolic effects: GIP receptor activation enhances fat metabolism and improves adipose tissue function, while GLP-1 receptor activation reduces appetite and gastric emptying. Phase 3 SURMOUNT trials showed mean weight reduction up to 22.5% — exceeding all prior single-agonist data.
Mechanism of Action
Co-activates GIP and GLP-1 receptors. GIP component enhances adipocyte lipolysis and reduces lipotoxicity; GLP-1 component drives CNS appetite suppression and insulin secretion. Synergistic combination outperforms either target alone.
Reported Benefits
- • Unprecedented weight loss outcomes in clinical trials (up to 22.5%)
- • Superior HbA1c reductions compared to GLP-1 monotherapy
- • Improved lipid profiles and reduction in liver fat
- • Enhanced adipose tissue function and reduced lipotoxicity
Potential Side Effects
- • Nausea and gastrointestinal upset (dose-dependent)
- • Decreased appetite leading to potential malnutrition if unmonitored
- • Injection site reactions
- • Theoretical risk of thyroid tumors similar to GLP-1s
Frequently Asked Questions
Why is Tirzepatide considered more potent than previous peptides?▼
What are the expected weight loss outcomes?▼
Can it help with metabolic syndrome beyond just weight loss?▼
For Research Reference Only
Not medical advice. Peptides may be regulated or restricted in your jurisdiction.
References
- 1.Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide. PubMed (2026). Al Ozairi E, et al.. pubmed.ncbi.nlm.nih.gov/42555627/ ↑
- 2.Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use. PubMed (2026). Peng DS, et al.. pubmed.ncbi.nlm.nih.gov/42541308/ ↑
- 3.Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data. PubMed (2026). Omura T, et al.. pubmed.ncbi.nlm.nih.gov/42535213/ ↑
- 4.Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review. PubMed (2026). Alawad AO, et al.. pubmed.ncbi.nlm.nih.gov/42534427/ ↑
Where to Source Tirzepatide
20 vendors listed · ranked most → least trusted · not an endorsement
Rankings are community-derived. Always independently verify COAs before any research use. PeptidePlaza is not affiliated with any vendor.
Sell Tirzepatide on PeptidePlaza
Get listed as a verified vendor and reach researchers directly.
Related Research Articles
From the PeptidePlaza research blog.